|
|
|
| Efficacy analysis of Methimazole and Propylthiouracil in the treatment of diffuse toxic goiter complicated with Hashimoto hyperthyroidism |
| LIN Hanying |
| Department of Endocrinology,the First People′s Hospital of Zhaoqing City |
|
|
|
|
Abstract Objective To investigate the efficacy of Methimazole and Propylthiouracil in the treatment of diffuse toxic goiter (Graves disease) complicated with Hashimoto hyperthyroidism and their influence on thyroid peroxidase antibody(TPOAb),thyroglobulin antibody (TgAb) and thyrotropin receptor antibody (TRAb).Methods A total of 98 patients with Graves disease complicated with Hashimoto hyperthyroidism treated in the Endocrine Clinic of the First People′s Hospital of Zhaoqing City from September 2018 to August 2019 were selected as the research objects.They were divided into the observation group (49 cases) and the control group (49 cases) according to random number table method.The observation group was treated with Methimazole,and the control group was treated with Propylthiouracil.The clinical efficacy,the changes of TPOAb,TGAb and TRAb indexes and the total incidence of adverse reactions were observed in the two groups.Results After treatment,the levels of TPOAb,TgAb,TRAb,free triiodothyrine (FT3),free thyroid hormone (FT4) in the two groups were lower than those before treatment,the proportions of hypermetabolic symptom reduction and thyroid stimulating hormone (TSH) in the two groups were higher than those before treatment,the levels of TPOAb,TgAb,TRAb,FT3,FT4 in the observation group were lower than those in the control group,the proportions of hypermetabolic symptom reduction and TSH in the observation group was higher than that in the control group,and the differences were statistically significant (P＜0.05).The total incidence of adverse reactions after treatment in the observation group was significantly lower than that in the control group,and the difference was statistically significant (P＜0.05).Conclusion For the treatment of Graves disease complicated with Hashimoto hyperthyroidism,Propylthiouracil and Methimazole can play a better therapeutic effect.Among them,Methimazole has a better therapeutic effect than Propylthiouracil,with less adverse reactions and high safety,which is worthy of wide clinical promotion.
|
|
|
|
|
|
| [1] |
中华医学会，中华医学会临床药学分会，中华医学会杂志社，等.甲状腺功能亢进症基层合理用药指南[J].中华全科医师杂志，2021，20（5）：515-519.
|
| [2] |
郑慧娟，魏璠，魏军平.Graves 病发病机制新进展[J].中国免疫学杂志，2017，33（4）：621-624.
|
| [3] |
周芳宇，王欣，谭贵琴，等.Graves 病细胞免疫学机制的研究进展[J].中国比较医学杂志，2020，30（3）：98-102，128.
|
| [4] |
鲍佳卉，邹俊杰.Graves 病发病免疫学机制研究进展[J].临床军医杂志，2021，49（1）：111-113.
|
| [5] |
马金刚，魏红丽，尚恒.Graves 病患者外周血T 细胞亚群与甲状腺功能及甲状腺自身抗体间的相关性分析[J].国际内分泌代谢杂志，2020，40（1）：21-26.
|
| [6] |
鲁江艳，舒仪琼.甲亢平消方联合西药治疗Graves 病合并甲状腺毒症性心脏病的疗效及对心肌酶、心电图及心脏结构与功能的影响[J].现代中西医结合杂志，2019，28（13）：1391-1396，1449.
|
| [7] |
刘凤，肖虎，柳丹，等.初诊Graves 病患者治疗前后血清氨基末端脑钠肽前体的水平变化[J].中国现代医学杂志，2018，28（22）：104-107.
|
| [8] |
李云倩，黄奕君，吕静美，等.Graves 病患者性激素水平变化及临床意义[J].中国实验诊断学，2018，22（12）：2131-2132.
|
| [9] |
张红菊，秦东平.甲巯咪唑治疗甲状腺功能亢进症的效果及对FT3、FT4、TSH 水平的影响[J].临床医学研究与实践，2019，4（9）：42-44.
|
| [10] |
刘秀娟.探究甲巯咪唑和丙硫氧嘧啶应用在甲状腺功能亢进中的疗效及对肝功能的影响效果[J].中外女性健康研究，2017，（13）：33-34.
|
| [11] |
中华医学会，中华医学会临床药学分会，中华医学会杂志社，等.中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志，2007，46（10）：876-882.
|
| [12] |
陈彦.甲巯咪唑与丙硫氧嘧啶对毒性弥漫性甲状腺肿甲状腺机能亢进症患者血清激素各指标水平的影响[J].抗感染药学，2018，15（4）：649-650.
|
| [13] |
张守堂，蒋东鹏，万国靖.甲巯咪唑与丙硫氧嘧啶治疗甲亢的临床疗效和安全性分析[J].世界最新医学信息文摘，2019，19（52）：178，186.
|
| [14] |
沈振芳，钱靖，焦雪花，等.甲巯咪唑片治疗甲状腺功能亢进患者的临床研究[J].中国临床药理学杂志，2020，36（18）：2769-2771.
|
| [15] |
邓丽萍，武红梅，乐有为.丙硫氧嘧啶与甲巯咪唑治疗甲状腺功能亢进症的临床效果比较[J].中国当代医药，2018，25（15）：61-63，67.
|
| [16] |
赵洪琼，田晓江，唐学文，等.基于FDA 不良事件数据库对甲巯咪唑与丙硫氧嘧啶药物风险信号的数据挖掘与评价[J].医药导报，2018，37（10）：1261-1266.
|
| [17] |
郭玲玲，童波，赖红琳，等.丙基硫氧嘧啶致抗中性粒细胞胞浆抗体阳性血管炎的临床分析[J].江西医药，2017，52（1）：79-80.
|
| [18] |
郑薇，王萱，李宁，等.格雷夫斯病及格雷夫斯眼病靶向TSHR 及IGF-1R 治疗策略展望[J].中华核医学与分子影像杂志，2020，40（7）：434-439.
|
|
|
|
